8th Annual ECD Medical Symposium Rochester, Minnesota

Ronald Go, MD & Gaurav Goyal, MD

Rochester, MN USA

8th ms

Symposium Attendees Mayo Group Picture 2023

Symposium Summary

Approximately 41 medical professionals from six countries attended the Annual ECD Colloque médical in 2023. Twelve oral abstracts were presented, along with an additional seven poster presentations. As an invited speaker, Mrinal Patnaik, MBBS, delivered a talk titled “Understanding monocyte-related disorders
including epigenetics and genomics.” Workshops on radiology and pathology were held, along with a “Meet the Experts” panel for attendees to discuss challenging situations. An evening reception provided time for discussions supporting current and future collaborations among this highly knowledgeable group of physicians and scientists, all interested in learning more about Erdheim-Chester Disease.

Programs with Symposium Agenda

Ordre du jour

Animateur	Diapositives de présentation	Video
Ronald Go, docteur en médecine Gaurav Goyal, docteur en médecine	Welcome & Meeting Overview	Welcome & Meeting Overview
Kathleen Brewer, Founder Paul Hendrie, MD	History of the ECDGAFocus on the Future	History of the ECDGAFocus on the Future
Mrinal Patnaik, MBBS	Understanding monocyte-related disorders including epigenetics and genomics	Understanding monocyte-related disorders including epigenetics and genomics
Benjamin Durham, docteur en médecine	RAF-independent MEK mutations drive histiocytic neoplasms in vivo and are sensitive to single agent ERK inhibition in patients	RAF-independent MEK mutations drive histiocytic neoplasms in vivo and are sensitive to single agent ERK inhibition in patients
Michelangelo Tesi, MD	Cluster analysis unveils the clinical spectrum of Erdheim-Chester Disease	Cluster analysis unveils the clinical spectrum of Erdheim-Chester Disease
Aldo A Acosta Medina, MD	Efficacy of MEK inhibitors of Erdheim-Chester disease	Efficacy of MEK inhibitors of Erdheim-Chester disease
Eli Diamond, docteur en médecine	Neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib	Neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib
Jérôme Razanamahery, docteur en médecine	Early changes in intermediate monocyte distribution correlate with relapse-free survival during follow-up in adult histiocytoses	Early changes in intermediate monocyte distribution correlate with relapse-free survival during follow-up in adult histiocytoses
Francesco Peyronel, MD,	Geographic clustering of Erdheim-Chester Disease in Italy and France	Geographic clustering of Erdheim-Chester Disease in Italy and France
Eli Diamond, docteur en médecine	A multinational series of 26 patients with mixed histiocytic neoplasms highlighting a diverse mutational landscape and superior efficacy of targeted therapies	A multinational series of 26 patients with mixed histiocytic neoplasms highlighting a diverse mutational landscape and superior efficacy of targeted therapies
Matt Slief, MD	A pilot study of patient-reported outcome measures among individuals with histiocytic neoplasm	A pilot study of patient-reported outcome measures among individuals with histiocytic neoplasm
Karen Rech, MD Jennifer Picarsic, docteur en médecine	Pathology mimics workshop	Pathology mimics workshop
Skand Shekhar, MD	Abnormalities of pituitary imaging and associated endocrine disorders in Erdheim-Chester disease	Abnormalities of pituitary imaging and associated endocrine disorders in Erdheim-Chester disease
Julien Haroch, MD, PhD Levi-Dan Azoulay, MD	Longitudinal assessment of cardiac involvement in Erdheim-Chester disease using cardiac magnetic resonance imaging	Longitudinal assessment of cardiac involvement in Erdheim-Chester disease using cardiac magnetic resonance imaging
Aishwarya Ravindran, MD	The phenotypic spectrum of malignant histiocytosis parallels the lineage subsets of monocytes, macrophages, and dendritic cells	Indisponible
Gordon Ruan, MD	Clinical features, molecular aberrations, treatments, and outcomes of malignant histiocytoses	Clinical features, molecular aberrations, traitements, and outcomes of malignant histiocytoses
Corrie Bach, MD	Radiology workshop	Radiology workshop
Eli Diamond, docteur en médecine Ron Go, MD Julien Haroche, docteur en médecine Eric Jacobsen, MD	No slide deck	Meet the Experts: Challenging situations and unanswered questions
Kathy Brewer	ECD Global Alliance Mission Forward	ECD Global Alliance Mission Forward

Photographies

Colloque médical

Medical Reception

Care Center Meeting